Gentronix
Katie joined the company in 2015 and is a cytogenetics and gene mutation Study Director. Prior to joining Gentronix, Katie worked in the Genetic Toxicology department of a leading pharmaceutical company for over 20 years, gaining extensive experience in performance and interpretation of GLP Genetic Toxicology studies.
This person is not in any offices
Gentronix
Gentronix provides services for the development of drugs and other chemicals in the cosmetics and personal care sectors.